Cardioprotective effect of thiotriazoline in cancer patients
Aim. To evaluate the effectiveness of morpholinium-methyl-triazolyl-thioacetate (thiotriazoline) as a cardioprotector in patients with non-Hodgkin’s lymphomas who received chemotherapy with the inclusion of anthracyclines.Material and methods. Fifty patients with non-Hodgkin’s lymphomas were examine...
Saved in:
Main Authors: | A. V. Koltsov, V. V. Tyrenko |
---|---|
Format: | Article |
Language: | Russian |
Published: |
«FIRMA «SILICEA» LLC
2023-02-01
|
Series: | Российский кардиологический журнал |
Subjects: | |
Online Access: | https://russjcardiol.elpub.ru/jour/article/view/5304 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Nuclear imaging of chemotherapy-induced cardiotoxicity
by: A. A. Ansheles, et al.
Published: (2021-03-01) -
Lifestyle and Pharmacological Interventions to Prevent Anthracycline-Related Cardiotoxicity in Cancer Patients
by: Luigi Spadafora, et al.
Published: (2025-06-01) -
Relationship between Chemotherapy and Atrial Fibrillation: Clinical Case
by: A. A. Avagimyan, et al.
Published: (2021-11-01) -
Heart failure in cancer patients
by: A. F. Khalirakhmanov, et al.
Published: (2022-01-01) -
Course of arterial hypertension during breast cancer chemotherapy with anthracyclines
by: E. N. Berezikova, et al.
Published: (2024-10-01)